tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Alkermes Reveals Promising Phase 1b Study Results

Alkermes Reveals Promising Phase 1b Study Results

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Alkermes (ALKS) has issued an announcement.

Alkermes plc has announced encouraging preliminary results from a phase 1b study of their new oral drug, ALKS 2680, aimed at treating narcolepsy type 2 and idiopathic hypersomnia. This milestone could be of great interest to investors tracking advancements in the biopharmaceutical sector, as the company progresses with a treatment that addresses sleep disorders with a novel mechanism of action.

For detailed information about ALKS stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1